Psychiatrie - Péče o duševní zdraví | Medireco Clinic

SKUTEK SE NESTAL. PŘESTO JI ŽENOU K PSYCHIATRIČCE

V úterý odvysílala Česká televize v dokumentární sérii Rozpleteno díl Moc bez taláru o moci znaleckých posudků a práci psychiatričky MUDr. Gabriely Leblové.

Diagnóza nepohodlný - Rozpleteno | Česká televize

V Česku končí ročně nedobrovolně na psychiatrii několik tisíc lidí. Jak kvalitní jsou odborné posudky, které vám mohou přepsat život?

MUDr. Gabriela Leblová: nejpilnější znalkyně v oboru psychiatrie a trvalý otazník nad objektivitou posudků

Znalecká činnost v České justici je dlouhodobě kritizována za nevyváženost v počtu přidělovaných posudků mezi jednotlivé znalce a za absenci transparentního a…

Zastavit krvácení umíme, co když ale dítě nebo kolega propadne depresi? Experti radí, jak poskytnout první pomoc duši

Do svých deseti let to byla veselá, bezproblémová dívka. Ale pak se něco stalo. Sofie se propadla do zármutku a plačtivých nálad. „V té době se dcera poprvé setkala se smrtí. Umřel jí pes, s nímž od malička vyrůstala. Ve stejném období přišla i o dědečka a na těžkou nemoc zemřel také chlapec...

Medical Care Situation of People with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in Germany

Background and Objective: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a severe illness with the hallmark symptom of Post-Exertional Malaise (PEM). Currently, no biomarkers or established diagnostic tests for ME/CFS exist. In Germany, it is estimated that over 300,000 people are affected by ME/CFS. Research from the United States and the UK shows that patients with ME/CFS are medically underserved, as they face barriers to medical care access and are dissatisfied with medical care. The first aim of the current research was to investigate whether patients with ME/CFS are medically underserved in Germany in terms of access to and satisfaction with medical care. Second, we aimed at providing a German-language version of the DePaul Symptom Questionnaire Short Form (DSQ-SF) as a tool for ME/CFS diagnostics and research in German-speaking countries. Materials and Methods: The current research conducted an online questionnaire study in Germany investigating the medical care situation of patients with ME/CFS. The questionnaire was completed by 499 participants who fulfilled the Canadian Consensus Criteria and reported PEM of 14 h or longer. Results: Participants frequently reported geographic and financial reasons for not using the available medical services. Furthermore, they reported low satisfaction with medical care by the physician they most frequently visited due to ME/CFS. The German version of the DSQ-SF showed good reliability, a one-factorial structure and construct validity, demonstrated by correlations with the SF-36 as a measure of functional status. Conclusions: Findings provide evidence that patients with ME/CFS in Germany are medically underserved. The German-language translation of the DSQ-SF provides a brief, reliable and valid instrument to assess ME/CFS symptoms to be used for research and clinical practice in German-speaking countries. Pathways to improve the medical care of patients with ME/CFS are discussed.

Blood tests for mental health problems | Eiko Fried

A new paper was published yesterday on a blood test for schizophrenia, by the same research team that in 2021 published a paper on a blood test for depression . The papers and...

Health system support among patients with ME/CFS in Switzerland

Objectives Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex chronic and debilitating multifactorial disease. Adequate patient care is challenged by poor knowledge among health care professionals and the historical misconception that the disease is psychological in nature. This study assessed the health-related challenges faced by patients with ME/CFS in Switzerland and examined whether they receive adequate health care. Methods Quantitative and qualitative data were collected through a self-administered questionnaire between June and September of 2021, among 169 patients with ME/CFS in Switzerland. Results The mean age at diagnosis was 38.8 years. Only one-third of ME/CFS affected children and youth were correctly diagnosed before their 18th birthday. The mean time from disease onset to diagnosis was 6.7 years, and patients had an average of 11.1 different appointments and 2.6 misdiagnoses. A poor diagnosis rate and insufficient disease knowledge among health professionals in Switzerland led 13.5% of the patients to travel abroad to seek a diagnosis. Most patients (90.5%) were told at least once that their symptoms were psychosomatic. Swiss patients expressed high dissatisfaction with the health system and indicated that physicians lacked knowledge regarding ME/CFS. Therapies prescribed by physicians or tried by patients, as well as their perceived efficacy, were described. Graded Exercise Therapy (GET) was perceived as harmful by patients, whereas pacing, complementary/alternative medicine, and dietary supplements and medications to alleviate symptoms were reported to be helpful to varying degrees. Conclusion This study highlights that poor disease knowledge among health care providers in Switzerland has led to high patient dissatisfaction, and delays in ME/CFS diagnoses and prescription of inappropriate therapies, thus adding to patient distress and disease burden.

[Article] The complex lived experience of schizophrenia diagnosis: a thematic analysis of online forum posts

109K subscribers in the schizophrenia community. Welcome! This is a community meant for a discussion of schizophrenia spectrum disorders, and related…

Comment vont les enfants ?

De nombreux indicateurs psychiques et physiques montrent que la jeunesse fait face à une crise de la santé mentale. Ces résultats proviennent généralement d’enquêtes se concentrant sur des tranches d’âge relativement élevées de la jeunesse (à partir de 15 ou 18 ans et allant jusqu’à 25 ans) et suivent rarement les répondants dans le temps.

The negative impact of the psychiatric model of chronic fatigue syndrome on doctors’ understanding and management of the illness

Background: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a disabling condition that greatly impacts the lives of sufferers. Many sufferers report problems getting a confirmatory d...

Wenn Struktur und Grenzen schaden: Das PDA-Profil in der Autismus-Spektrum-Störung

Der Autismus-Verband Deutschland definiert die Autismus-Spektrum-Störung als „Störungen der Informations- und Wahrnehmungsverarbeitung, die sich auf die Entwicklung der sozialen Interaktion, der Kommunikation und des Verhaltensrepertoires auswirken“ (Autismus Deutschland e.V., 2022). Zumeist benötigen Menschen mit dieser Diagnose viel Struktur und vorhersehbare Rahmenbedingungen, um die Vielzahl an Reizen und Umweltinformationen ordnen und angemessen verarbeiten zu können. Hierfür werden nicht s

Nový zvrat v případu Viktorky: Tejc připouští návrat od opilství k vraždě - Seznam Zprávy

Ministerstvo spravedlnosti prověřuje posudek, kvůli němuž policie překvalifikovala zabití tříleté Viktorky na opilství. Ministr Tejc připouští návrat k trestnému činu vraždy a kontroluje i další práci znalkyně Gabriely Leblové.

Occurrence of Psychosis and Bipolar Disorder in Individuals With ADHD Treated With Stimulants

This systematic review and meta-analysis evaluates the association between psychosis or bipolar disorder and stimulant treatment among individuals with attention-deficit/hyperactivity disorder.

Psychiatry at the Margins | Awais Aftab | Substack

Exploring critical, philosophical, and scientific debates in psychiatric practice and the psy-sciences. Click to read Psychiatry at the Margins, by Awais Aftab, a Substack publication with tens of thousands of subscribers.

Methylphenidate and the risk of psychosis in adolescents and young adults: a population-based cohort study

Background There is a clinical concern that prescribing methylphenidate, the most common pharmacological treatment for attention-deficit hyperactivity disorder (ADHD), might increase the risk of psychotic events, particularly in young people with a history of psychosis. We aimed to determine whether the risk of psychotic events increases immediately after initiation of methylphenidate treatment or, in the longer term, 1 year after treatment initiation in adolescents and young adults with and without a previously diagnosed psychotic disorder. Methods In this cohort study, we used population-based observational data from the Swedish Prescribed Drug Register, the National Patient Register, and the Total Population Register, three population-based registers containing data on all individuals in Sweden, to attain data on sex, birth, death, migration, medication use, and psychotic events for all eligible participants. We screened individuals on these registers to identify those receiving methylphenidate treatment, and who were aged 12–30 years at the start of treatment, for their inclusion in the study. We used a within-individual design to compare the incidence of psychotic events in these individuals during the 12-week periods immediately before and after methylphenidate initiation. Longer term risk was assessed by comparing the incidence of psychotic events 12 weeks before methylphenidate initiation and during a 12-week period one calendar year before the initiation of methylphenidate with the incidence of these events during the 12-week period one calendar year after methylphenidate initiation. We estimated the incidence rate ratios (IRR) and 95% CIs of psychotic events after the initation of methylphenidate treatment, relative to the events before treatment, which were defined as any hospital visit (inpatient admission or outpatient attendance, based on data from the National Patient Register) because of psychosis, using the International Classification of Diseases version 10 definition. Analyses were stratified by whether the individual had a history of psychosis. Findings We searched the Swedish Prescribed Drug Register to find eligible individuals who had received methylphenidate between Jan 1, 2007 and June 30, 2012. 61 814 individuals were screened, of whom 23 898 (38·7%) individuals were assessed and 37 916 (61·3%) were excluded from the study because they were outside of the age criteria at the start of treatment, they had immigrated, emigrated, or died during the study period, or because they were administered other ADHD medications. The median age at methylphenidate initiation was 17 years, and a history of psychosis was reported in 479 (2·0%) participants. The IRR of psychotic events in the 12-week period after initiation of methylphenidate treatment relative to that in the 12-week period before treatment start was 1·04 (95% CI 0·80–1·34) in adolescents and young adults without a history of psychosis and 0·95 (0·69–1·30) among those with a history of psychosis. Interpretation Contrary to clinical concerns, we found no evidence that initiation of methylphenidate treatment increases the risk of psychotic events in adolescents and young adults, including in those individuals with a history of psychosis. Our study should reassure clinicians considering initiating methylphenidate treatment for ADHD in adolescents and young adults, and it challenges the widely held view in clinical practice that methylphenidate should be avoided, or its use restricted, in individuals with a history of psychosis. Funding Swedish Research Council, National Institute of Mental Health, UK National Institute of Health Research Nottingham Biomedical Research Centre.